Antibodies to Target Tau Protein in Brain Diseases

This patent describes specific antibodies designed to bind to the tau protein, aiming to slow down or stop brain diseases linked to tau, like Alzheimer's.

What it covers

This patent focuses on creating special proteins called antibodies that can find and attach to a specific target: the tau protein. The abstract states these antibodies "specifically bind tau." By binding to tau, these antibodies are designed to "inhibit or delay tau-associated pathologies" which are the harmful changes in the brain caused by tau. This could also delay "associated symptomatic deterioration," meaning the worsening of disease symptoms. For example, such an antibody might prevent abnormal tau from clumping together in brain cells, a process seen in neurodegenerative diseases.

What it doesn't cover

• —Does not cover small molecule drugs or other non-antibody treatments for tau-associated pathologies.
• —Does not cover antibodies that target other proteins or biological markers not related to tau.
• —Does not cover diagnostic methods for tau-associated pathologies, only therapeutic intervention.
• —Does not cover antibodies that do not specifically bind to the tau protein as described.
• —Does not cover methods of treatment that do not involve administering these specific antibodies.

The clever bit

The novelty lies in the specific design of antibodies that can precisely recognize and bind to the tau protein. This specific binding is intended to disrupt the harmful processes caused by tau, thereby inhibiting or delaying the progression of brain pathologies and their symptoms.

Why it matters

Tau protein plays a critical role in several neurodegenerative diseases, including Alzheimer's disease and chronic traumatic encephalopathy. When tau misbehaves, it forms tangles inside brain cells, disrupting their function and leading to cell death. Developing antibodies that can target and neutralize problematic tau could offer a way to treat or slow the progression of these devastating conditions, which currently have limited effective treatments.

Real-world examples

• 1.Experimental treatments for Alzheimer's disease
• 2.Research into chronic traumatic encephalopathy (CTE) therapies
• 3.Drug development for frontotemporal dementia (FTD)
• 4.Antibody-based therapies for neurodegenerative disorders